Investor's Business Daily

Regeneron (REGN) shares spiked 9.8% to 252.17 after the company announced results for a late state trial that showed eye medication Eylea improved the vision of patients suffering from myopic choroidal neovascularization. The medication is approved in the U.S. and EU for treatment for "wet" age-related macular degeneration.

View Comments (0)